Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

  • STATUS
    Recruiting
  • End date
    Jun 15, 2025
  • participants needed
    870
  • sponsor
    Merck Sharp & Dohme Corp.
Updated on 9 June 2021
Investigator
Toll Free Number
Primary Contact
Centre Francois Baclesse ( Site 0459) (0.0 mi away) Contact
+190 other location

Summary

A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.

Details
Condition Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive, Urinary Bladder Cancer, Muscle-invasive
Treatment cisplatin, Placebo, Gemcitabine, Pembrolizumab, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Clinical Study IdentifierNCT03924856
SponsorMerck Sharp & Dohme Corp.
Last Modified on9 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Have a histologically confirmed diagnosis of urothelial carcinoma (UC) / muscle invasive bladder cancer (MIBC) (T2-T4aN0M0 or T1-T4aN1M0) with predominant (50%) urothelial histology
Have clinically non-metastatic bladder cancer (N1 M0) determined by imaging (computed tomography (CT) or magnetic resonance imaging (MRI) of the chest/abdomen/pelvis
Be deemed eligible for Radical Cystectomy (RC) + Pelvic Lymph Node Dissection (PLND)
Have adequate organ function
Male and female participants are eligible to participate if they agree to the contraception use as per study protocol
Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria

Has received any prior systemic treatment for MIBC or non-invasive muscle bladder cancer (NMIBC - prior treatment for NMIBC with intravesical BCG/chemotherapy is permitted) or prior therapy with an anti- programmed cell death 1 (PD-1), anti-programmed cell death ligand 1/ ligand 2 (PD-L1/L2), or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
Has N2 disease or metastatic disease (M1) as identified by imaging
Is cisplatin-ineligible, as defined by meeting any one of the cisplatin ineligibility criteria as per protocol
Has a known additional malignancy that is progressing or has required active anti-cancer treatment 3 years of study randomization with certain exceptions
Has received prior systemic anticancer therapy including investigational agents within 3 years of randomization or any radiotherapy to the bladder
Has undergone partial cystectomy of the bladder to remove any NMIBC or MIBC
Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention
Has a diagnosis of immunodeficiency or has a known history of human immunodeficiency virus (HIV) infection, Hepatitis B infection or known active Hepatitis C infection
Has a known psychiatric or substance abuse disorder
Has had an allogenic tissue/solid organ transplant
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note